Response Genetics, Inc. (RGDX) Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell

Company to Celebrate Initial Public Offering On NASDAQ


ADVISORY, June 7, 2007 (PRIME NEWSWIRE) --



 What:
 Kathleen Daneberg, CEO of Response Genetics, Inc. (RGDX), will
 preside over the closing bell to celebrate the Company's initial
 public offering on NASDAQ.

 Where:
 NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

 When:
 Friday, June 8, 2007 at 4 p.m. ET

 Contacts:
 Jennifer K. Zimmons, Ph.D
 Strategic Growth International
 212.838.1444
 jzimmons@sgi-ir.com

 NASDAQ MarketSite:
 Jolene Libretto; 646.441.5220; 347.219.9539
 Jolene.Libretto@NASDAQ.com

Feed Information:

The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.

Radio Feed:

An audio transmission of the closing bell is also available from 3:50 p.m. to 4:05 p.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.

Webcast:

A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Response Genetics, Inc. (RGDX):

Response Genetics, Inc. ("RGI") (Nasdaq:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.